GSK Formally Launches $10.6 Billion All-Cash Tender Offer for Nuvalent at $124.00/Share
NUVL sits 74% above its 52-week low of $71.13.
Summary
GSK has formally launched its all-cash tender offer to acquire Nuvalent, Inc. for $124.00 per share, with the Nuvalent board recommending shareholders accept the offer.
Key Events · M&A and Partnerships · NUVL
-
Tender Offer Commenced
Harmony Row Acquisition Co., a subsidiary of GSK, has formally commenced its all-cash tender offer to acquire all outstanding shares of Nuvalent, Inc.
-
Offer Price Confirmed
The offer price is $124.00 per share in cash, net to the seller, without interest and subject to applicable withholding taxes.
-
Board Recommendation
Nuvalent's Board of Directors has unanimously recommended that shareholders accept the offer and tender their shares.
-
Offer Expiration
The tender offer and withdrawal rights will expire at one minute following 11:59 p.m., Eastern Time, on July 14, 2026, unless extended or terminated.
Analysis · NUVL · Life Sciences
This filing marks the formal commencement of GSK's tender offer to acquire Nuvalent, Inc. for $124.00 per share in cash. This is the critical execution phase of the previously announced $10.6 billion merger agreement, moving from an announced deal to an active offer for shareholders to tender their shares. The Nuvalent Board has unanimously recommended shareholders accept the offer, which is priced at a slight premium to the current trading price and near the 52-week high, providing a clear exit for investors.
At the time of this filing, NUVL was trading at $123.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $71.13 to $123.69. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.